Arion (France)

Simple SummaryRacehorses compete in short (‘sprinters’); medium (‘milers’) or long distance (‘stayers’) races. Sprinters are thought to naturally have a shorter stride than stayers; but no study has objectively tested this theory. Here, using known race distance to categorize racehorses into one of the three aforementioned categories together with a stride tracking device that objectively measures locomotion; this study demonstrates that peak stride length in racehorses is a heritable trait that is different in sprinters versus stayers prior to them even racing at that distance. In training, sprinters took shorter strides of higher frequency and were faster to cover furlongs in race-speed training sessions from a standing start than stayers. These stride data were recorded during training sessions before the horses raced and thus categorised as ‘sprinters’ or ‘stayers’. Stride length during training did not predict later racing success. This study provides the first objective insight into locomotory differences between sprinters and stayers. Such information when coupled with the trainer’s experience/eye could help them choose the most suitable race for each individual horse; to benefit both its health and safety on the track.Racehorses competing in short (i.e., ‘sprinters’), middle- or longer-distance (i.e., ‘stayers’) flat races are assumed to have natural variation in locomotion; sprinters having an innately shorter stride than stayers. No study has objectively tested this theory. Here, racehorses (n = 421) were categorised as sprinters, milers or stayers based on known race distance (n = 3269 races). Stride parameters (peak length and frequency) of those racehorses were collected from prior race-pace training sessions on turf (n = 2689; ‘jumpout’, n = 1013), using a locomotion monitoring device. Pedigree information for all 421 racehorses was extracted to three-generations. In training, sprinters had a shorter stride of higher frequency and covered consecutive furlongs faster than stayers (p < 0.001). Relatively short or longer stride did not predict race success, but stayers had greater race success than sprinters (p < 0.001). Peak stride length and frequency were moderately heritable (h2 = 0.15 and 0.20, respectively). In conclusion, differences in stride were apparent between sprinters and stayers (e.g., shorter stride in sprinters) during routine training, even after accounting for their pedigree. Objective data on stride characteristics could supplement other less objectively obtained parameters to benefit trainers in the appropriate selection of races for each individual racehorse.

The racing industry is supported by a predominance of female stablehands and work riders, but few become professional jockeys. Female jockeys have recently had notable race success. No study has assessed whether the sex of the rider may subtly influence racehorse physiology to affect performance. Here, using a validated exercise tracking system (the 'Equimetre'™) that records many physiological parameters simultaneously, this study characterised racehorse cardiovascular (heart rate, heart rate recovery) and biomechanical (stride length and frequency) parameters at various exercise intensities (slow canter to hard gallop) to address the question whether any parameter varied according to sex of the rider. A total of 530 Thoroughbreds, varying in age (2-7 years old) and sex (including geldings), from one racing yard in Australia, completed a total of 3,568 exercise sessions, monitored by a single trainer, on varying track surfaces (sand, turf, or fibre). Different work riders,103 in total (male, n = 66; female, n = 37) of which n = 43 were current or past registered professional jockeys, participated in the study. Data were analysed using analysis of variation (ANOVA) or mixed-effect models, as appropriate. Sex of the rider did not influence (P > 0.05) racehorse speed nor stride length at any training intensity. Racehorse heart rate and peak heart rate increased with training intensity (P < .001), with no difference according to sex of rider (P > 0.05). Racehorse heart rate recovery was influenced by sex of the rider, but only at the extremes of the reversed, usual training intensity on each surface (e.g. heart rate after galloping on sand was significantly lower with male riders, P = 0.03). Finally, analysis of 52,464 race results indicated a similar chance of a top-three placing for male and female jockeys. In conclusion, this study, using objectively obtained data, demonstrates for the first time no overt effect of the rider's sex on racehorse physiology in training and performance in racing. Such data could encourage greater female participation in racing and improve access of female jockeys to better quality mounts in racing events.

The aims of this study performed in ewes were: (1) to confirm in this animal model the effects on bone of ovariectomy (OVX) alone or associated with Lentaron (L), a potent peripheral aromatase inhibitor, used to amplify the effects of OVX and (2) to evaluate the effects of a new selective estrogen receptor modulator (SERM; MDL 103,323) on bone remodeling. Thirty-nine old ewes were divided into five groups: sham (n = 7); OVX (n = 8); OVX + L (n = 8); OVX + L + MDL; 0.1 mg/kg per day (n = 8); and OVX + L + MDL 1 mg/kg per day (n = 8). The animals were treated for 6 months. Biochemical markers of bone turnover (urinary excretion of type 1 collagen C-telopeptide [CTX], serum osteocalcin [OC], and bone alkaline phosphatase [BAP]) were measured each month. Bone biopsy specimens were taken at the beginning and after death at the end of the experiment. Bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry (DXA) on the lumbar spine and femur. OVX induced a significant increase in biochemical markers. This effect was the highest after 3 months for CTX (+156% vs. sham) and after 4 months for OC and BAP (+74% and +53% vs. sham, respectively). L tended to amplify the effect of OVX on OC and BAP. OVX induced significant increases in the porosity, eroded, and osteoid surfaces in cortical bone but no effect was observed in cancellous bone. MDL treatment reduced the bone turnover as assessed by bone markers, which returned to sham levels as well as histomorphometry both in cortical and in cancellous bone. Cancellous osteoid thickness decreased by 27% (p < 0.05), mineralizing perimeter by 81% (p < 0.05), and activation frequency by 84% (p < 0.02) versus OVX + L. Femoral and spinal BMD were increased by MDL and tended to return to the sham values. The effects of OVX on bone turnover were different on cortical and cancellous bone. These effects on cortical bone were reflected by changes in biochemical markers. MDL markedly reduces bone turnover and increases BMD suggesting that this new agent may prevent postmenopausal bone loss.